Results 151 to 160 of about 5,459 (165)
N-Acetyl-leucine in progressive CACNA1A ataxia: A case series
Background: CACNA1A-related disorders are rare and progressive; to date, there is no approved treatment. Trials with N-acetyl-leucine (NAL) demonstrated efficacy in disorders featuring ataxia, cognitive impairment, and epilepsy.
Argirios Dinopoulos +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
The complexities of CACNA1A in clinical neurogenetics
Journal of Neurology, 2021Maartje Pennings +2 more
exaly
Instrumented gait analysis defines the walking signature of CACNA1A disorders
Journal of Neurology, 2021Gregor Wenning +2 more
exaly
Seizure response to carbamazepine in a patient with CACNA1A-associated epilepsy: A case report
Seizure: the Journal of the British Epilepsy Association, 2023Paolo Solla, Francesca Pinna
exaly
CACNA1A Nonsense Mutation is Associated With Basilar‐Type Migraine and Episodic Ataxia Type 2
Headache, 2009Matthew Robbins
exaly

